NOVAREMED-AG
15.9.2020 10:24:14 CEST | Business Wire | Press release
Novaremed AG (Novaremed), a clinical-stage Swiss biopharmaceutical company, today announced that it has raised CHF2.5 million from its existing shareholders in an oversubscribed new financing round. This brings the total financing raised by the company, since its inception, to CHF23.5 million. The additional proceeds will be used to prepare for the initiation of a Phase 2b clinical study in the US of its novel drug candidate, NRD135S.E1, for the treatment of Painful Diabetic Peripheral Neuropathy (PDPN). The U.S. Food and Drug Administration (FDA) had recently cleared an Investigational New Drug (IND) application for the Phase 2b clinical study.
“The oversubscription of the new financing is a strong endorsement by our shareholders of the major milestone achieved by the company by securing an IND clearance from the FDA”, said Subhasis Roy, M. Com, MBA, CEO/COO of Novaremed.
Novaremed also announced today that its PCT patent application covering a targeted therapy to treat pain and inflammation was published on July 30, 2020 (Publication No. WO 2020/1522226). It was titled “Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity”. This PCT application allows Novaremed to file patent applications and seek protection in most major countries worldwide. The national patent applications, if granted, will provide protection for Novaremed’s technology without a gap in patent protection until 2039/40.
Dr. Eli Kaplan, Novaremed’s Founder and Chief Innovator, commented, “This PCT patent application is a significant step in being able to protect our unique compound for neuropathic pain for many years to come. It is particularly important now as we get closer to beginning our Phase 2b clinical trial in patients with PDPN.”
Novaremed is participating at International Association for the Study of Pain (IASP) sponsored conference “Virtual Series on Pain & Expo”, which is being held virtually this year between September 2020 and March 2021. Novaremed’s poster abstract on the results of the Phase 2a Proof of Concept study has been accepted for the virtual poster gallery.
Notes to the Editor:
About Novaremed
Novaremed Ltd, a wholly owned subsidiary of Novaremed AG was founded in 2008 in Israel and Novaremed AG was founded in 2017 in Switzerland. Novaremed Ltd is developing NRD135S.E1, an orally active non-opioid small molecule with a novel mechanism of action against PDPN. In a Phase 2a Proof of Concept study, NRD135S.E1 showed clinically relevant reduction in patient-reported pain and an excellent safety and tolerability profile. Novaremed Ltd is currently preparing to conduct a Phase 2b study in PDPN patients in USA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200915005582/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hovione Appoints Stefan Doboczky as Chief Executive Officer8.9.2026 13:16:00 CEST | Press release
Chairman of the Board of Directors Stefan Doboczky to take over operational leadership of the family-owned pharmaceutical technology and services group on April 1, 2027 Hovione Holding AG today announced the appointment of Stefan Doboczky as Chief Executive Officer (CEO), effective April 1, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908358544/en/ Stefan Doboczky, Chief Executive Officer of Hovione. Photo credit: Karl Michalski. Stefan Doboczky has served as Chairman of the Board of Directors of Hovione Holding AG since 2024, where he has been instrumental in shaping the company’s strategy and vision. He will step down as Chairman on assuming the role of Chief Executive Officer. Founded in 1959, Hovione is a family-owned pharmaceutical technology and services group serving the industry worldwide, with more than 2,600 employees, four FDA-inspected production and R&D sites in Europe, the United States and China, an
Hirect to Showcase In-House Developed 6,000 HP Electric Locomotive Propulsion System and Indian Railways Contract at InnoTrans 20268.9.2026 13:09:00 CEST | Press release
Vertically integrated propulsion systems provider announces first full MEMU trainset system order Hirect (NSE: HIRECT), a premier manufacturer of heavy-duty electrical and power electronic systems for rail network rolling stock, will debut its new 6,000 HP locomotive propulsion system at InnoTrans 2026, Berlin, 22 - 25 September. The company will also announce the first development order for the complete trainset propulsion system, which will deliver the power and traction package for Indian Railways' next-generation Mainline Electric Multiple Unit (MEMU) fleet. Hirect's 6,000 HP electric locomotive propulsion system — designed, engineered and manufactured entirely in-house, including its liquid-cooled IGBT traction inverters/converters and proprietary control software — completed its acceptance regime this year after successfully hauling loaded freight in a WAG-9 locomotive under India's severe duty cycles and demanding thermal operating environment. The qualification opens one of the
NIQ Expands Product Intelligence Across Western Europe, Strengthening the Foundation for AI-Driven Commerce8.9.2026 12:32:00 CEST | Press release
Enhanced capabilities connect product attributes with market performance, helping brands and retailers understand shopper choice today and prepare for AI-mediated discovery NIQ (NYSE: NIQ), a leading consumer intelligence company, today announced the expansion of NIQ Product Insights (NPI) across Western Europe, strengthening its Product Intelligence portfolio to help brands and retailers better understand what drives shopper choice and category growth. The expansion brings enhanced product intelligence capabilities to Austria, Belgium, Italy, Netherlands, Portugal, Spain and Switzerland, building on existing availability in France, Germany, Ireland, and the United Kingdom. As shoppers, and increasingly the digital and AI-powered tools that guide them, evaluate products against specific health, wellness, sustainability, and ingredient preferences, product attributes are becoming an increasingly important part of commerce’s intelligence infrastructure. Brands and retailers need more tha
Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 20268.9.2026 12:30:00 CEST | Press release
Compass will debut Change the Tune in TRD, a new U.S. healthcare provider (HCP) education campaign for treatment-resistant depression (TRD) at Booth #901Seven poster presentations include new health economics and outcomes research (HEOR) data alongside encore analyses from the COMP360 clinical development program Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced its participation at Psych Congress 2026, taking place in New Orleans, LA, from September 14-19. The Company will debut Change the Tune in TRD, a new educational campaign for U.S. HCPs focused on TRD, and present new HEOR data examining the burden of TRD alongside encore presentations from its COMP360 psilocybin clinical development program. Change the Tune in TRD: Advancing HCP Education Change the Tune in TRD is a new educational initiative for U.S. HCPs exploring the neurobiology and navigating care pathways in TRD.
HTEC and Modular Extend MAX and Mojo to Google TPU, Cutting AI Hardware Enablement from Years to Months8.9.2026 12:17:00 CEST | Press release
Advanced compiler and runtime engineering validates a faster, reusable path for bringing AI workloads to new silicon without rebuilding the software stack HTEC, a global AI-first engineering and technology services company, and Modular have demonstrated Modular's AI software stack running on Google's TPU architecture. Presented at ModCon 2026, the work shows that support for a new silicon target can be delivered by extending an existing software foundation rather than rebuilding it for each accelerator. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908670401/en/ HTEC, a global AI-first engineering and technology services company, and Modular have demonstrated Modular's AI software stack running on Google's TPU architecture. Presented at ModCon 2026, the work shows that support for a new silicon target can be delivered by extending an existing software foundation rather than rebuilding it for each accelerator. The project
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom